ESR1 and breast carcinoma: A tumour-suppressive relationship between these nuclear receptors was illustrated by co-treatment with mineralocorticoids and retinoic acid receptor-stimulating retinoids [163], highlighting another potential therapeutic pathway worth characterising in the setting of breast cancer resistant to standard ER-targeted therapies.